Pharvaris (PHVS) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Pharvaris, a biopharmaceutical company focusing on oral treatments for hereditary angioedema (HAE), has scheduled its annual shareholder meeting for June 28, 2024. The meeting details and documentation will be accessible on the company’s website in the ‘Investors’ section, as well as on the SEC’s website. Interested shareholders are invited to register for the event following the instructions provided in the meeting notice.
For further insights into PHVS stock, check out TipRanks’ Stock Analysis page.
